Holen Sie sich die Stockscreener-App
93.63
0.10%
-0.09
Handel nachbörslich:
93.63
Schlusskurs vom Vortag:
$93.72
Offen:
$94.87
24-Stunden-Volumen:
842.61K
Relative Volume:
0.97
Marktkapitalisierung:
$6.42B
Einnahmen:
$217.17M
Nettoeinkommen (Verlust:
$-202.68M
KGV:
-40.66
EPS:
-2.3028
Netto-Cashflow:
$-156.63M
1W Leistung:
-2.70%
1M Leistung:
+7.28%
6M Leistung:
-5.81%
1J Leistung:
+63.46%
1-Tages-Spanne:
$93.00
$96.64
1-Wochen-Bereich:
$86.76
$97.42
52-Wochen-Spanne:
$57.20
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
93.63 | 6.42B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-11-25 | Eingeleitet | Citigroup | Buy |
| 2025-11-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Green Thumb Just Made an Unprecedented Move. Here's What It Means for GTBIF Investors. - The Motley Fool
RYTM: Strong HO launch, global reach, and next-gen therapies drive growth in rare obesity markets - TradingView
RYTM: Strong HO launch, robust pipeline, and next-gen therapies to address key patient needs - TradingView
Guggenheim Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $143 - 富途牛牛
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology - marketscreener.com
Hidden hunger in rare obesity: new UK study finds severe hyperphagia missed - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Gem with 46.76% Upside Potential - DirectorsTalk Interviews
A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter Results - Sahm
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
RYTM Maintained by Canaccord Genuity -- Price Target Raised to $143 - GuruFocus
RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Rhythm Pharmaceuticals Price Target Raised to $143.00/Share From $140.00 by Canaccord Genuity - Moomoo
Rhythm Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:RYTM) 2026-05-07 - Seeking Alpha
Rhythm Pharmaceuticals Analysts Boost Their Forecasts Following Upbeat Q1 Results - Sahm
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $143 - Moomoo
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2026 Earnings Call Transcript - Insider Monkey
Is It Too Late To Consider Rhythm Pharmaceuticals (RYTM) After Its Recent Share Price Surge - Sahm
Rhythm Pharmaceuticals Q1 2026 Earnings: Stock Rises 8% on Imcivree Revenue BeatNews and Statistics - IndexBox
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $130 to $144 - Moomoo
Full Transcript: Rhythm Pharmaceuticals Q1 2026 Earnings Call - Sahm
Rhythm Pharmaceuticals to Participate in Bank of America Conference on May 13, 2026 - geneonline.com
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $136 - Moomoo
Rhythm Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Rhythm CEO to speak at Bank of America healthcare conference May 13 - Stock Titan
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch By Investing.com - Investing.com Australia
MSN Money - MSN
Why Rhythm Pharmaceuticals Stock Triumphed on Tuesday - The Motley Fool
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Rhythm Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance
Rhythm Pharmaceuticals (RYTM) grows Q1 2026 revenue but posts larger net loss - Stock Titan
Rhythm Pharmaceuticals Weighs Long Term IMCIVREE Data And Growth Potential - Yahoo Finance
Rhythm Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Stifel raises Rhythm Pharmaceuticals stock price target on launch By Investing.com - Investing.com South Africa
Does EU IMCIVREE Expansion for Hypothalamic Obesity Change The Bull Case For Rhythm (RYTM)? - Sahm
Stifel raises Rhythm Pharmaceuticals stock price target on launch - Investing.com UK
Rhythm Pharmaceuticals Q1 2026 slides: revenue beats on HO launch - Investing.com
Earnings call transcript: Rhythm Pharmaceuticals Q1 2026 revenue beats forecast - Investing.com Nigeria
Rhythm Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) Surpasses Q1 Estimates as U.S. Hypothalamic Obesity Launch Accelerates - ChartMill
Q1 2026 Rhythm Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Rhythm Pharmaceuticals (Nasdaq: RYTM) grows IMCIVREE sales and expands approvals - Stock Titan
Rhythm Pharmaceuticals Q1 revenue rises 84% - TradingView
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q1 Revenue $60.1M, Vs. FactSet Est of $55.8M - Moomoo
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update - The Manila Times
After FDA approval, rare-obesity drug draws 150 start forms in 6 weeks - Stock Titan
Rhythm Pharmaceuticals (RYTM) Revenue Ramp With US$201.9m TTM Loss Tests Bullish Narratives - Sahm
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):